179 related articles for article (PubMed ID: 25377919)
1. Application of a novel regulatable Cre recombinase system to define the role of liver and gut metabolism in drug oral bioavailability.
Henderson CJ; McLaughlin LA; Osuna-Cabello M; Taylor M; Gilbert I; McLaren AW; Wolf CR
Biochem J; 2015 Feb; 465(3):479-88. PubMed ID: 25377919
[TBL] [Abstract][Full Text] [Related]
2. Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system.
Finn RD; McLaren AW; Carrie D; Henderson CJ; Wolf CR
J Pharmacol Exp Ther; 2007 Jul; 322(1):40-7. PubMed ID: 17435107
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of CYP3A-mediated midazolam metabolism by anchusan in rats.
Saito Y; Nishimura Y; Kurata N; Iwase M; Aoki K; Yasuhara H
J Pharmacol Sci; 2011; 115(3):399-407. PubMed ID: 21358120
[TBL] [Abstract][Full Text] [Related]
4. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Intestinal and Hepatic CYP3A-Mediated Metabolism of Midazolam in Children Using a Physiological Population Pharmacokinetic Modelling Approach.
Brussee JM; Yu H; Krekels EHJ; Palić S; Brill MJE; Barrett JS; Rostami-Hodjegan A; de Wildt SN; Knibbe CAJ
Pharm Res; 2018 Jul; 35(9):182. PubMed ID: 30062590
[TBL] [Abstract][Full Text] [Related]
6. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
7. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
[TBL] [Abstract][Full Text] [Related]
8. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
Thummel KE; O'Shea D; Paine MF; Shen DD; Kunze KL; Perkins JD; Wilkinson GR
Clin Pharmacol Ther; 1996 May; 59(5):491-502. PubMed ID: 8646820
[TBL] [Abstract][Full Text] [Related]
9. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
[TBL] [Abstract][Full Text] [Related]
10. Evidence that cytochrome b5 and cytochrome b5 reductase can act as sole electron donors to the hepatic cytochrome P450 system.
Henderson CJ; McLaughlin LA; Wolf CR
Mol Pharmacol; 2013 Jun; 83(6):1209-17. PubMed ID: 23530090
[TBL] [Abstract][Full Text] [Related]
11. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
12. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
13. siRNA-mediated knockdown of P450 oxidoreductase in rats: a tool to reduce metabolism by CYPs and increase exposure of high clearance compounds.
Burke RS; Somasuntharam I; Rearden P; Brown D; Deshmukh SV; DiPietro MA; DiMuzio J; Eisenhandler R; Fauty SE; Gibson C; Gindy ME; Hamilton KA; Knemeyer I; Koeplinger KA; Kwon HW; Lifsted TQ; Menzel K; Patel M; Pudvah N; Rudd DJ; Seitzer J; Strapps WR; Prueksaritanont T; Thompson CD; Hochman JH; Carr BA
Pharm Res; 2014 Dec; 31(12):3445-60. PubMed ID: 24980206
[TBL] [Abstract][Full Text] [Related]
14. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
Tomalik-Scharte D; Doroshyenko O; Kirchheiner J; Jetter A; Lazar A; Klaassen T; Frank D; Wyen C; Fätkenheuer G; Fuhr U
Eur J Clin Pharmacol; 2008 Oct; 64(10):1033-5. PubMed ID: 18587567
[No Abstract] [Full Text] [Related]
15. Effect of ursodeoxycholic acid on the pharmacokinetics of midazolam and CYP3A in the liver and intestine of rats.
Kurosawa S; Uchida S; Ito Y; Yamada S
Xenobiotica; 2009 Feb; 39(2):162-70. PubMed ID: 19255942
[TBL] [Abstract][Full Text] [Related]
16. The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene.
Fang C; Zhang QY
J Pharmacol Exp Ther; 2010 Jul; 334(1):156-63. PubMed ID: 20400470
[TBL] [Abstract][Full Text] [Related]
17. Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir.
Kirby BJ; Collier AC; Kharasch ED; Whittington D; Thummel KE; Unadkat JD
Drug Metab Dispos; 2011 Jun; 39(6):1070-8. PubMed ID: 21406602
[TBL] [Abstract][Full Text] [Related]
18. The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers.
Pentikis HS; Connolly M; Trapnell CB; Forbes WP; Bettenhausen DK
Pharmacotherapy; 2007 Oct; 27(10):1361-9. PubMed ID: 17896891
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Kato A; Takano M
J Pharm Pharmacol; 1999 Jan; 51(1):67-72. PubMed ID: 10197420
[TBL] [Abstract][Full Text] [Related]
20. Dietary regulation of mouse intestinal P450 expression and drug metabolism.
Zhang P; Jia K; Fang C; Zhou X; Ding X; Zhang QY
Drug Metab Dispos; 2013 Feb; 41(2):529-35. PubMed ID: 23160819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
